Biosynth Leadership Transition: Matt Gunnison Named CEO
Biosynth, a well-established global supplier of essential raw materials and services for the life sciences industry, has announced significant changes within its leadership team. Matt Gunnison is stepping into the role of Chief Executive Officer, with his appointment effective immediately. Alongside him, Kieran Murphy has been appointed as Chairman of the Board of Directors, marking a new chapter for the company.
A Legacy of Growth and Innovation
Matt succeeds Urs Spitz, who led Biosynth through a period of remarkable growth. Under Utt's guidance, the company has fortified its presence in the life sciences sector. Despite stepping down from the CEO position, Urs will maintain his role on the Board, continuing to support the strategic direction of the company.
Visionary Leadership and Future Goals
In a statement, Kugan Sathiyanandarajah, a prominent partner at KKR and Head of Europe for KKR’s Health Care Strategic Growth strategy, expressed gratitude for Urs's impactful contributions. “We are excited to welcome Matt as our new CEO. His vision and extensive experience will be pivotal in leading the company forward,” Kugan said.
Matt highlighted his enthusiasm for joining the company, stating, “I am thrilled to join Biosynth at such an exciting time. The foundation laid under Urs's leadership is strong, and I look forward to collaborating with our talented team to drive further growth and innovation, impacting global health outcomes.”
Kieran Murphy echoed this sentiment, stating, “It’s a privilege to be appointed Chairman. I am excited to guide the company’s continued growth and innovation in the life sciences industry. With the right leadership in place, I am confident in our trajectory.”
Profiles of Leadership
Matt Gunnison brings an impressive background to Biosynth, serving as CEO of Gamma Biosciences, a platform he co-founded with KKR. With nearly twenty years of experience in healthcare and life sciences, he has held prominent roles, including head of corporate development at GE Healthcare.
Kieran Murphy also holds a distinguished career, having served as a senior advisor to KKR and Chairman at Gamma Biosciences since 2022. His extensive experience in corporate leadership includes significant positions at GE Healthcare.
Joining Matt and Kieran is Eric Simpson, now Head of Corporate Development for Biosynth, who previously served as Vice President at Gamma Biosciences.
About Biosynth
Biosynth is dedicated to supplying critical materials that fortify life sciences supply chains. With a focus on the pharmaceutical and diagnostic sectors, the company thrives where chemistry meets biology, and innovation meets quality. With a vast research product portfolio and comprehensive manufacturing services, Biosynth specializes in Complex Chemicals, Peptides, and Key Biologics. The company is headquartered in Switzerland and is financially backed by KKR and Ampersand Capital Partners.
About KKR
KKR stands as a leading investment firm that manages alternative assets and provides capital markets and insurance solutions. Its strategy focuses on generating attractive investment returns by navigating the market with a patient approach while supporting growth in portfolio companies.
Frequently Asked Questions
1. Who has been appointed as the new CEO of Biosynth?
Matt Gunnison has been named the new CEO of Biosynth.
2. What role does Kieran Murphy play in the company now?
Kieran Murphy has been appointed as the Chairman of the Board of Directors at Biosynth.
3. What impressive background does Matt Gunnison bring?
Matt has nearly two decades of experience in healthcare and previously served as CEO of Gamma Biosciences.
4. How does Biosynth contribute to the life sciences sector?
Biosynth supplies critical raw materials and services essential for pharmaceutical and diagnostic sectors.
5. What are the goals under the new leadership team?
The new leadership aims to drive growth, innovation, and significant contributions to global health outcomes.
